Legend Biotech announced new presentations at ASCO 2026, including preliminary Phase 1 results for LB2102, a CAR-T therapy targeting DLL3 in relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma. The data show manageable safety and early clinical activity, marking progress in extending CAR-T treatments to solid tumors. Additionally, updated data on CARVYKTI, their approved CAR-T therapy for multiple myeloma, reinforce its efficacy and safety, with subgroup analyses and immune-related side effect profiles presented. The company will also host an investor event to discuss these advancements, highlighting its strategic focus on expanding CAR-T therapies beyond blood cancers.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
